HK1039272A1 - Prodrug compounds and process for preparation thereof - Google Patents

Prodrug compounds and process for preparation thereof

Info

Publication number
HK1039272A1
HK1039272A1 HK01108566.6A HK01108566A HK1039272A1 HK 1039272 A1 HK1039272 A1 HK 1039272A1 HK 01108566 A HK01108566 A HK 01108566A HK 1039272 A1 HK1039272 A1 HK 1039272A1
Authority
HK
Hong Kong
Prior art keywords
leu
prodrug
prodrugs
therapeutic agent
ssala
Prior art date
Application number
HK01108566.6A
Other languages
English (en)
Inventor
Thomas J Lobl
Vincent Dubois
Anne-Marie Fernandez
Sanjeev Gangwar
Evan Lewis
Matthew H Nieder
Andre Trouet
Peter Viski
Geoffrey T Yarranton
Original Assignee
Coulter Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coulter Pharm Inc filed Critical Coulter Pharm Inc
Publication of HK1039272A1 publication Critical patent/HK1039272A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
HK01108566.6A 1998-12-11 2001-12-06 Prodrug compounds and process for preparation thereof HK1039272A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11179398P 1998-12-11 1998-12-11
US11931299P 1999-02-08 1999-02-08
PCT/US1999/030393 WO2000033888A2 (en) 1998-12-11 1999-12-10 Prodrug compounds and process for preparation thereof

Publications (1)

Publication Number Publication Date
HK1039272A1 true HK1039272A1 (en) 2002-04-19

Family

ID=26809248

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01108566.6A HK1039272A1 (en) 1998-12-11 2001-12-06 Prodrug compounds and process for preparation thereof

Country Status (14)

Country Link
EP (1) EP1144011B1 (pt)
JP (1) JP2003518000A (pt)
AT (1) ATE460180T1 (pt)
AU (1) AU773420B2 (pt)
CA (1) CA2354766A1 (pt)
CY (1) CY1111094T1 (pt)
DE (1) DE69942128D1 (pt)
DK (1) DK1144011T3 (pt)
ES (1) ES2342637T3 (pt)
HK (1) HK1039272A1 (pt)
IL (2) IL143666A0 (pt)
NZ (1) NZ512171A (pt)
PT (1) PT1144011E (pt)
WO (1) WO2000033888A2 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE212661T1 (de) 1998-01-23 2002-02-15 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
IL140700A0 (en) 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
WO2000069472A2 (en) 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
AU6358900A (en) * 1999-07-22 2001-02-13 Newbiotics, Inc. Enzyme catalyzed anti-infective therapeutic agents
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
CA2378187C (en) 1999-07-22 2011-09-13 Newbiotics, Inc. Methods for treating therapy-resistant tumors
DE10018617A1 (de) * 2000-01-13 2001-10-31 Joerg G Moser Cyclodextrin-Dimere mit Peptid-Spacerstrukturen zur Entgiftung von pharmazeutischen Wirkstoffen hohen Nebenwirkungspotentials
MXPA02009019A (es) 2000-03-15 2003-02-12 Du Pont Pharm Co Farmacos antineoplasticos de objetivo, que se desdoblan por la peptidasa y su uso terapeutico.
JP2004501875A (ja) 2000-06-14 2004-01-22 メダレックス，インコーポレイティド トリペプチドプロドラッグ化合物
EP1294405A2 (en) * 2000-06-14 2003-03-26 Corixa Corporation Prodrug compounds cleavable by thimet oligopeptidase
WO2001095943A2 (en) * 2000-06-14 2001-12-20 Medarex, Inc. Prodrug compounds with an oligopeptide having an isoleucine residue
AU2001286727A1 (en) 2000-08-24 2002-03-04 Coulter Pharmaceutical, Inc. Prodrugs activated by plasmin and their use in cancer chemotherapy
PL365685A1 (en) * 2000-10-27 2005-01-10 Aventis Pharma S.A. A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
JP2006516948A (ja) * 2000-11-14 2006-07-13 ニュー リバー ファーマシューティカルズ インコーポレイテッド 硫酸アバカビルを含有する新規な薬剤化合物および同化合物の製造ならびに使用方法
EP1355675A1 (en) * 2001-01-30 2003-10-29 Universite Catholique De Louvain Anti-tumor compounds
CN101671335A (zh) 2001-05-31 2010-03-17 梅达莱克斯公司 细胞毒素、其有用的前体药物、连接基团和稳定剂
AU2002316539C1 (en) * 2001-06-11 2008-10-30 Medarex, Inc. CD10-activated prodrug compounds
FR2825928B1 (fr) * 2001-06-18 2004-04-02 Ecole Norm Superieure Cachan Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine
WO2003094972A2 (en) * 2002-05-10 2003-11-20 Boehringer Ingelheim Pharma Gmbh & Co Kg Fap-activated anti-tumor prodrugs
US7378386B2 (en) 2002-07-15 2008-05-27 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives
US7678386B2 (en) 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7879801B2 (en) * 2002-07-15 2011-02-01 Board Of Regents, The University Of Texas System Compositions comprising cell-impermeant duramycin derivatives
US7384909B2 (en) 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
US7511124B2 (en) 2002-07-15 2009-03-31 Board Of Regents, The University Of Texas System Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
CA2542946A1 (en) 2003-10-28 2005-05-12 Medtronic, Inc. Methods of preparing crosslinked materials and bioprosthetic devices
WO2005072061A2 (en) 2004-02-02 2005-08-11 Biosight Ltd. Conjugates for cancer therapy and diagnosis
WO2006095345A2 (en) 2005-03-08 2006-09-14 Ramot At Tel-Aviv University Ltd. Targeted drug-carrying bacteriophages
EP1993608A1 (en) * 2006-03-10 2008-11-26 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
ES2678060T3 (es) 2006-12-01 2018-08-08 E. R. Squibb & Sons, L.L.C. Anticuerpos, en particular, anticuerpos humanos, que se unen a CD22 y usos de los mismos
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
EP2121667B1 (en) 2007-02-21 2016-06-08 E. R. Squibb & Sons, L.L.C. Chemical linkers with single amino acids and conjugates thereof
EP1977765A1 (en) * 2007-04-03 2008-10-08 Diatos Peptide prodrugs
SI2833905T1 (en) 2012-04-04 2018-08-31 Halozyme, Inc. Combination therapy with hyaluronidase and tumane-directed taxane
AU2013369261B2 (en) * 2012-12-28 2018-08-09 Cobiores Nv Minimally toxic prodrugs
MX365465B (es) 2013-03-21 2019-06-04 Sanofi Aventis Deutschland Sintesis de productos peptidicos que contienen imida ciclica.
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
US20140364368A1 (en) * 2013-06-06 2014-12-11 Massachusetts Institute Of Technology Stimulus responsive nanocomplexes and methods of use thereof
US11058701B2 (en) 2015-12-03 2021-07-13 Biosight Ltd. Cytarabine conjugates for cancer therapy
RU2747528C2 (ru) 2015-12-03 2021-05-06 Биосайт Лтд. Соли конъюгатов для лечения рака
CN109021065B (zh) * 2017-06-08 2021-10-01 复旦大学 一种制备海兔毒素Dolastatin10的方法
JP2023554520A (ja) 2020-12-22 2023-12-27 コビオレス エヌヴイ テトラペプチド部分を含む化合物
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3167679D1 (en) * 1980-03-31 1985-01-24 Inst Int Pathologie Cellulaire Pharmaceutical forms, their preparation and compositions containing the same
US5155210A (en) * 1990-09-11 1992-10-13 Brunswick Corporation Methods of conjugating actinomycin d
WO1994019376A1 (en) * 1993-02-26 1994-09-01 Drug Delivery System Institute, Ltd. Polysaccharide derivative and drug carrier
PT769967E (pt) * 1994-08-19 2008-02-18 Univ Catholique Louvain Conjugados que compreendem um agente antitumoral e a sua utilização
CA2265476A1 (en) * 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
WO1998052966A1 (en) * 1997-05-19 1998-11-26 The Johns Hopkins University School Of Medecine Tissue specific prodrug
WO1999002175A1 (en) * 1997-07-10 1999-01-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
IL136167A0 (en) * 1997-12-02 2001-05-20 Merck & Co Inc Conjugates useful in the treatment of prostate cancer

Also Published As

Publication number Publication date
WO2000033888A9 (en) 2001-05-10
AU2373300A (en) 2000-06-26
DE69942128D1 (de) 2010-04-22
PT1144011E (pt) 2010-06-16
CY1111094T1 (el) 2015-10-07
JP2003518000A (ja) 2003-06-03
EP1144011B1 (en) 2010-03-10
CA2354766A1 (en) 2000-06-15
IL143666A0 (en) 2002-04-21
DK1144011T3 (da) 2010-07-05
AU773420B2 (en) 2004-05-27
WO2000033888A2 (en) 2000-06-15
ATE460180T1 (de) 2010-03-15
EP1144011A2 (en) 2001-10-17
NZ512171A (en) 2004-07-30
IL143666A (en) 2009-02-11
ES2342637T3 (es) 2010-07-09
WO2000033888A3 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
IL143666A0 (en) Prodrug compounds and process for preparation thereof
EP3830090B1 (en) 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists and methods and uses therefor
US7442386B2 (en) Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
US5760072A (en) Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy
Kumar et al. Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer
CA2478066A1 (en) Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
WO1997018207A3 (en) Novel macrocyclic compounds as metalloprotease inhibitors
IL133585A0 (en) Soluble prodrugs of paclitaxel
JP2002543163A (ja) 癌および前立腺疾患のための治療としての結合体
AU2002324723A1 (en) Synthesis and use of reagents for improved DNA lipofection and/or slow release pro-drug and drug therapies
AU2002359164A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
IL159843A0 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
CA2501651A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
JP2016538281A (ja) 血液脳関門を通過するタンパク質ホスファターゼ阻害剤
WO2001085142A8 (en) Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
JP2003528851A (ja) セラミド誘導体と使用方法
WO2014013995A1 (ja) KRAS遺伝子発現抑制RNAi医薬組成物
DE69917281T2 (de) Coumarin und damit verwandte aromatische polymere prodrugs
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
WO2015186770A1 (ja) ＣＫＡＰ５遺伝子発現抑制ＲＮＡｉ医薬組成物
Sflakidou et al. Synthesis and antiproliferative activities of steroidal lactam conjugates bearing a new nitrogen mustard
JPH09235293A (ja) 新規トリテルペン
CN103183722A (zh) 一种乙二醛酶ⅰ抑制剂及其制备方法和医药用途
JPS6317840B2 (pt)
RU2724882C1 (ru) 1,1'-(Гексан-1,6-диил)бис(3-(((1R,4aS,10aR)-7-изопропил-1,4а-диметил-1,2,3,4,4а,9,10,10а-октагидрофенантрен-1-ил)метил)мочевина, проявляющая ингибирующее действие в отношении фермента тирозил-ДНК-фосфодиэстеразы 1 человека и увеличивающая активность темозоломида в отношении клеток глиобластомы

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131210